Publications by authors named "Irma Convertino"

Claim this Profile
S
Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation.
Giulia Valdiserra, Nadia Mores, Rosalba Elisabetta Rocchi, Laura Sottosanti, Patrizia Felicetti, Irma Convertino

Front Drug Saf Regul· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database.
Sara Ferraro, Emiliano Cappello, Marco Fornili, Irma Convertino, Marco Bonaso

Drug Saf· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world.
Irma Convertino, Luciane Cruz Lopes, Nicole Pratt, Ylenia Ingrasciotta, Marco Tuccori

Front Pharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy.
Fernanda Lacerda da Silva Machado, Martín Cañás, Martín A Urtasun, Gustavo H Marín, Flavia Caixeta Albuquerque, Irma Convertino

Ther Innov Regul Sci· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option.
Sara Ferraro, Irma Convertino, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso

Expert Opin Drug Discov· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Safety and Relevant Issues in the Real-World.
Maria Antonietta Barbieri, Natasha Irrera, Irma Convertino

Pharmaceuticals (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use.
Sara Ferraro, Emiliano Cappello, Claudia Bartolini, Irma Convertino, Lorenzo Bertani

Eur J Gastroenterol Hepatol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison.
Fernanda Lacerda da Silva Machado, Martín Cañás, Svetlana V Doubova, Martín A Urtasun, Gustavo H Marín, Irma Convertino

Regul Toxicol Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy.
Irma Convertino, Massimiliano Cazzato, Silvia Tillati, Sabrina Giometto, Rosa Gini

Front Pharmacol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence.
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso

Expert Opin Drug Discov· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis.
Irma Convertino, Valentina Lorenzoni, Rosa Gini, Giuseppe Turchetti, Elisabetta Fini

Pharmaceuticals (Basel)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall.
Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra

Expert Opin Drug Discov· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future.
Marco Tuccori, Irma Convertino, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello

Expert Opin Drug Discov· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study.
Irma Convertino, Sabrina Giometto, Rosa Gini, Massimiliano Cazzato, Marco Fornili

J Clin Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases.
Irma Convertino, Massimiliano Cazzato, Sabrina Giometto, Rosa Gini, Giulia Valdiserra

Sci Rep· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons.
Irma Convertino, Ersilia Lucenteforte, Rosa Gini, Valentina Lorenzoni, Massimiliano Cazzato

Clin Exp Rheumatol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs.
Sara Ferraro, Marco Tuccori, Irma Convertino, Giulia Valdiserra, Emiliano Cappello

Br J Clin Pharmacol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
Marco Tuccori, Sara Ferraro, Irma Convertino, Emiliano Cappello, Giulia Valdiserra

MAbs· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.
Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra

Drug Saf· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients.
Irma Convertino, Marco Tuccori, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello

Crit Care· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance.
Sara Ferraro, Irma Convertino, Luca Leonardi, Corrado Blandizzi, Marco Tuccori

Expert Opin Drug Saf· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis.
Irma Convertino, Stefano Salvadori, Alessandro Pecori, Maria Teresa Galiulo, Sara Ferraro

Drug Saf· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies.
Sara Ferraro, Luca Leonardi, Irma Convertino, Corrado Blandizzi, Marco Tuccori

Front Pharmacol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The usefulness of listening social media for pharmacovigilance purposes: a systematic review.
Irma Convertino, Sara Ferraro, Corrado Blandizzi, Marco Tuccori

Expert Opin Drug Saf· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis